Marathon Pharmaceuticals, LLC

Release Summary

Marathon Pharmaceuticals, LLC, today announced that the FDA has granted approval of EMFLAZA™ (deflazacort) for the treatment of Duchenne muscular dystrophy in patients 5 years and older.

Marathon Pharmaceuticals, LLC